Shanghai MicroPort Endovascular MedTech Past Earnings Performance
Past criteria checks 4/6
Shanghai MicroPort Endovascular MedTech has been growing earnings at an average annual rate of 28.1%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been growing at an average rate of 28.1% per year. Shanghai MicroPort Endovascular MedTech's return on equity is 16.6%, and it has net margins of 51.8%.
Key information
28.1%
Earnings growth rate
25.2%
EPS growth rate
| Medical Equipment Industry Growth | 16.0% |
| Revenue growth rate | 28.1% |
| Return on equity | 16.6% |
| Net Margin | 51.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Investors Met With Slowing Returns on Capital At Shanghai MicroPort Endovascular MedTech (SHSE:688016)
Dec 16
Calculating The Fair Value Of Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHSE:688016)
Nov 27Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Attractive Earnings Are Not All Good News For Shareholders
Nov 06There's No Escaping Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Muted Earnings Despite A 31% Share Price Rise
Oct 01Earnings Miss: Shanghai MicroPort Endovascular MedTech Co., Ltd. Missed EPS By 16% And Analysts Are Revising Their Forecasts
Aug 29Shanghai MicroPort Endovascular MedTech (SHSE:688016) Will Want To Turn Around Its Return Trends
Aug 15Investors Don't See Light At End Of Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Tunnel
Jun 29These 4 Measures Indicate That Shanghai MicroPort Endovascular MedTech (SHSE:688016) Is Using Debt Safely
Apr 29Shanghai MicroPort Endovascular MedTech's (SHSE:688016) Earnings Are Weaker Than They Seem
Apr 09Shanghai MicroPort Endovascular MedTech Co., Ltd.'s (SHSE:688016) Business Is Trailing The Market But Its Shares Aren't
Mar 25Revenue & Expenses Breakdown
How Shanghai MicroPort Endovascular MedTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,268 | 657 | 197 | 126 |
| 30 Jun 24 | 1,353 | 616 | 195 | 145 |
| 31 Mar 24 | 1,260 | 552 | 190 | 160 |
| 31 Dec 23 | 1,187 | 492 | 187 | 173 |
| 30 Sep 23 | 1,121 | 444 | 193 | 167 |
| 30 Jun 23 | 1,059 | 421 | 191 | 161 |
| 31 Mar 23 | 924 | 358 | 160 | 139 |
| 31 Dec 22 | 897 | 357 | 153 | 138 |
| 30 Sep 22 | 839 | 367 | 125 | 123 |
| 30 Jun 22 | 781 | 346 | 117 | 114 |
| 31 Mar 22 | 745 | 338 | 113 | 115 |
| 31 Dec 21 | 685 | 316 | 105 | 102 |
| 30 Sep 21 | 652 | 302 | 97 | 99 |
| 30 Jun 21 | 618 | 279 | 92 | 91 |
| 31 Mar 21 | 569 | 257 | 90 | 85 |
| 31 Dec 20 | 470 | 215 | 79 | 73 |
| 30 Sep 20 | 414 | 192 | 76 | 61 |
| 30 Jun 20 | 377 | 177 | 72 | 53 |
| 31 Mar 20 | 341 | 156 | 71 | 51 |
| 31 Dec 19 | 334 | 142 | 71 | 50 |
| 30 Sep 19 | 306 | 127 | 65 | 42 |
| 30 Jun 19 | 282 | 115 | 60 | 37 |
| 31 Mar 19 | 257 | 103 | 66 | 37 |
| 31 Dec 18 | 231 | 91 | 53 | 30 |
| 31 Dec 17 | 165 | 63 | 32 | 20 |
| 31 Dec 16 | 125 | 41 | 28 | 20 |
Quality Earnings: 688016 has a high level of non-cash earnings.
Growing Profit Margin: 688016's current net profit margins (51.8%) are higher than last year (39.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688016's earnings have grown significantly by 28.1% per year over the past 5 years.
Accelerating Growth: 688016's earnings growth over the past year (47.9%) exceeds its 5-year average (28.1% per year).
Earnings vs Industry: 688016 earnings growth over the past year (47.9%) exceeded the Medical Equipment industry -8.8%.
Return on Equity
High ROE: 688016's Return on Equity (16.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 18:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai MicroPort Endovascular MedTech Co., Ltd. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jingning Long | Chasing Securities |
| Jian Jun Zou | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |